Takeda announces u.s. fda approval of supplemental new drug application (snda) for iclusig® (ponatinib) in adult patients with newly diagnosed ph+ all

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has approved the supplemental new drug application (snda) for iclusig® (ponatinib) for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all) in combination with chemotherapy. this indication is approved under accelerated approval based on minimal residual disease (mrd)-negative complet.
TAK Ratings Summary
TAK Quant Ranking